rifampicin 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |

Stem definitionDrug idCAS RN
antibiotics, rifamycin derivatives 2377 13292-46-1

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • rifampicin
  • rifampin
  • refampicin
  • rifadin
  • rifadine
  • rifaldazine
  • rifaldin
  • rifaprodin
A semisynthetic antibiotic produced from Streptomyces mediterranei. It has a broad antibacterial spectrum, including activity against several forms of Mycobacterium. In susceptible organisms it inhibits DNA-dependent RNA polymerase activity by forming a stable complex with the enzyme. It thus suppresses the initiation of RNA synthesis. Rifampin is bactericidal, and acts on both intracellular and extracellular organisms. (From Gilman et al., Goodman and Gilman's The Pharmacological Basis of Therapeutics, 9th ed, p1160)
  • Molecular weight: 822.95
  • Formula: C43H58N4O12
  • CLOGP: 2.49
  • LIPINSKI: 3
  • HAC: 16
  • HDO: 6
  • TPSA: 220.15
  • ALOGS: -4.30
  • ROTB: 5
  • Status: OFP
    • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

DoseUnitRoute
0.60 g O
0.60 g P

ADMET properties:

PropertyValueReference
BDDCS (Biopharmaceutical Drug Disposition Classification System) 2 Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine) 7 % Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose) 24.30 µM/kg/day Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BA (Bioavailability) 70 % Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H
Vd (Volume of distribution) 0.97 L/kg Lombardo F, Berellini G, Obach RS
CL (Clearance) 3.50 mL/min/kg Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma) 0.20 % Lombardo F, Berellini G, Obach RS
t_half (Half-life) 3.80 hours Lombardo F, Berellini G, Obach RS
S (Water solubility) 1.40 mg/mL Bocci G, Oprea TI, Benet LZ

Predicted pharmacokinetic/toxicological properties (PK-AZ):

PropertyDescriptionValueUnitConfidenceSimilarity
azlogd74 LogD at pH 7.4 1.426 High 0.87
caco2-efflux Caco-2 efflux ratio (BA/AB) 9.817 High 0.87
caco2-intrinsic-papp Caco-2 intrinsic apparent permeability 6.012 10^-6 cm/s High 0.87
dh-clint Dog hepatocyte intrinsic clearance 3.126 uL/min/10^6 cells High 0.87
dppb Dog plasma protein binding (% unbound) 22.870 % High 0.87
fcs-ppb Fetal calf serum protein binding (% unbound) 28.330 % High 0.87
herg hERG pIC50 4.522 pIC50 High 0.87
hh-clint Human hepatocyte intrinsic clearance 1.531 uL/min/10^6 cells High 0.87
hlm-clint Human liver microsomal intrinsic clearance 4.236 uL/min/mg protein High 0.87
hppb Human plasma protein binding (% unbound) 22.420 % High 0.87
kinase-safety-class ACVR2B,ACVRL1,AURKA,AXL,BRAF,BTK,CAMK2B,CAMK2D,CDK5,CDK9,DDR1,DYRK1B,EIF2AK3,EPHB4,ERBB2,GRK2,GSK3B,ITK,JAK2,JAK3,KDR,MAP2K6,MAP3K7,MAPK10,MAPK7,MAPK9,MAPKAPK2,NTRK2,PDK1,PDK2,PDK4,PIK3CA,PIK3CB,PIK3CD,PIK3CG,PIM2,PRKDC,SIK2,STK33,SYK,TEK,TGFBR1,TTK,ZAP70 44
kinase-selectivity-class AXL,CDK4,GRK2,MAP2K6,TEK 5
mdck-mdr1-bcrp-efflux MDCK-MDR1-BCRP efflux ratio 1.977 High 1
mdck-mdr1-efflux MDCK-MDR1 efflux ratio 12.417 High 0.87
mh-clint Mouse hepatocyte intrinsic clearance 4.989 High 0.87
mppb Mouse plasma protein binding (% unbound) 13.870 High 0.87
nih-mdck-mdr1-efflux NIH MDCK-MDR1 efflux ratio 31.189 High 0.87
pfas-class PFAS structural alert (1 = True, 0 = False) 0
pld-class Phospholipidosis risk class (1 = positive, 0 = negative) 1 Moderate 0.67
pppb Pig plasma protein binding (% unbound) 31.070 % High 0.87
rat-kpuu-brain Rat brain Kpuu 0.025 % High 1
rh-clint Rat hepatocyte intrinsic clearance 2.307 uL/min/10^6 cells High 0.87
rh-fuinc Rat hepatocyte fraction unbound in incubation 58.720 % High 0.87
rppb Rat plasma protein binding (% unbound) 22.710 % High 0.87
solubility-dd Solubility at pH 7.4 in DMSO 826.038 uM High 0.87

Approvals:

DateAgencyCompanyOrphan
May 21, 1971 FDA SANOFI AVENTIS US

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Drug reaction with eosinophilia and systemic symptoms 1772.21 16.60 610 26264 42148 90559425
Drug interaction 903.45 16.60 706 26168 275747 90325826
Paradoxical drug reaction 822.09 16.60 214 26660 5552 90596021
Drug resistance 754.59 16.60 298 26576 30151 90571422
Eosinophilia 397.84 16.60 186 26688 28347 90573226
Drug-induced liver injury 347.41 16.60 255 26619 90063 90511510
Immune reconstitution inflammatory syndrome 281.74 16.60 98 26776 6921 90594652
Acute hepatic failure 271.62 16.60 133 26741 22428 90579145
Acute kidney injury 228.10 16.60 369 26505 320018 90281555
Jaundice 225.94 16.60 133 26741 32384 90569189
Rash maculo-papular 219.70 16.60 142 26732 40791 90560782
Tuberculosis 206.98 16.60 92 26782 12457 90589116
Immune reconstitution inflammatory syndrome associated tuberculosis 200.73 16.60 43 26831 460 90601113
Mycobacterium avium complex infection 190.98 16.60 64 26810 4034 90597539
Tuberculoma of central nervous system 189.99 16.60 39 26835 333 90601240
Pneumatosis intestinalis 181.54 16.60 59 26815 3378 90598195
Pathogen resistance 165.05 16.60 69 26805 8046 90593527
Drug ineffective 149.92 16.60 804 26070 1383494 89218079
Cholestasis 147.38 16.60 106 26768 36193 90565380
Hepatotoxicity 146.49 16.60 116 26758 45726 90555847
Drug ineffective for unapproved indication 146.34 16.60 136 26738 66508 90535065
Drug level decreased 137.31 16.60 64 26810 9666 90591907
Hepatocellular injury 127.83 16.60 89 26785 28869 90572704
Product use in unapproved indication 124.34 16.60 294 26580 335942 90265631
Virologic failure 108.68 16.60 36 26838 2188 90599385
Hidradenitis 102.17 16.60 41 26833 4306 90597267
Optic neuritis 98.67 16.60 51 26823 9627 90591946
Hepatic cytolysis 98.26 16.60 78 26796 30838 90570735
Pyrexia 96.44 16.60 419 26455 660066 89941507
Pulmonary tuberculosis 88.00 16.60 38 26836 4796 90596777
Transaminases increased 87.66 16.60 79 26795 37113 90564460
Pregnancy with implant contraceptive 86.76 16.60 35 26839 3726 90597847
Hypertransaminasaemia 85.11 16.60 55 26819 15770 90585803
Type 2 lepra reaction 84.43 16.60 15 26859 52 90601521
Glomerulonephritis minimal lesion 84.12 16.60 20 26854 352 90601221
Infusion related reaction 83.84 16.60 12 26862 416768 90184805
Optic neuropathy 83.19 16.60 31 26843 2667 90598906
Sinusitis 81.85 16.60 5 26869 343083 90258490
Mycobacterial infection 81.58 16.60 29 26845 2181 90599392
Hepatic encephalopathy 79.37 16.60 50 26824 13722 90587851
Disseminated tuberculosis 77.13 16.60 31 26843 3268 90598305
Tubulointerstitial nephritis 76.41 16.60 62 26812 25281 90576292
Alopecia 74.35 16.60 27 26847 495044 90106529
Off label use 72.16 16.60 565 26309 1101687 89499886
Nasopharyngitis 70.60 16.60 17 26857 407087 90194486
Wound 70.53 16.60 5 26869 302975 90298598
Hepatic failure 70.18 16.60 72 26802 39656 90561917
Hepatitis 69.58 16.60 95 26779 70644 90530929
Pancreatitis haemorrhagic 68.45 16.60 19 26855 630 90600943
Labelled drug-drug interaction medication error 67.12 16.60 46 26828 14536 90587037
Systemic lupus erythematosus 67.04 16.60 13 26861 361883 90239690
Thrombocytopenia 66.95 16.60 173 26701 208552 90393021
Atypical mycobacterial infection 66.39 16.60 23 26851 1603 90599970
Pancytopenia 62.63 16.60 121 26753 120142 90481431
Methaemoglobinaemia 61.62 16.60 28 26846 3987 90597586
Immunosuppressant drug level decreased 61.34 16.60 20 26854 1156 90600417
Arthropathy 60.23 16.60 17 26857 366225 90235348
Multiple organ dysfunction syndrome 60.11 16.60 87 26787 68249 90533324
Pain 60.07 16.60 129 26745 996212 89605361
Joint swelling 58.13 16.60 39 26835 503261 90098312
Renal tubular necrosis 57.91 16.60 42 26832 14513 90587060
Choroiditis 57.68 16.60 14 26860 270 90601303
Pericarditis 56.15 16.60 7 26867 270144 90331429
Hyperbilirubinaemia 54.96 16.60 40 26834 13896 90587677
Metabolic acidosis 53.58 16.60 74 26800 55602 90545971
Hepatic function abnormal 53.00 16.60 67 26807 46221 90555352
Latent tuberculosis 52.88 16.60 23 26851 2953 90598620
Discomfort 52.63 16.60 9 26865 274326 90327247
Fatigue 52.43 16.60 172 26702 1153851 89447722
Condition aggravated 52.11 16.60 328 26546 595217 90006356
Anti-cyclic citrullinated peptide antibody positive 51.99 16.60 5 26869 236428 90365145
Peripheral swelling 51.88 16.60 29 26845 413077 90188496
Multiple-drug resistance 51.88 16.60 31 26843 7745 90593828
Fall 50.88 16.60 41 26833 481769 90119804
Status epilepticus 50.30 16.60 43 26831 18831 90582742
Aspergillus infection 49.48 16.60 34 26840 10789 90590784
Pain in extremity 49.27 16.60 37 26837 450492 90151081
Rheumatoid arthritis 49.19 16.60 23 26851 362591 90238982
Toxic optic neuropathy 48.93 16.60 12 26862 242 90601331
Contusion 48.73 16.60 8 26866 251208 90350365
Type 2 diabetes mellitus 48.33 16.60 3 26871 203241 90398332
Cystic fibrosis pancreatic 48.00 16.60 9 26865 45 90601528
Ototoxicity 47.81 16.60 19 26855 1945 90599628
Renal impairment 47.63 16.60 100 26774 105321 90496252
Pulmonary cavitation 47.33 16.60 16 26858 1035 90600538
Mechanical urticaria 47.21 16.60 14 26860 590 90600983
Contraindicated product administered 47.11 16.60 18 26856 320121 90281452
Anticoagulation drug level decreased 46.20 16.60 9 26865 57 90601516
Synovitis 46.15 16.60 20 26854 329732 90271841
Psoriatic arthropathy 44.89 16.60 7 26867 228328 90373245
Face oedema 44.37 16.60 44 26830 23274 90578299
Type IV hypersensitivity reaction 43.83 16.60 22 26852 3904 90597669
Agranulocytosis 43.83 16.60 53 26821 34949 90566624
Oligoarthritis 43.67 16.60 13 26861 555 90601018
Tuberculosis gastrointestinal 43.35 16.60 12 26862 394 90601179
Drug eruption 43.34 16.60 53 26821 35354 90566219
Hypoprothrombinaemia 43.09 16.60 12 26862 403 90601170
Ocular toxicity 43.07 16.60 15 26859 1062 90600511
Vascular purpura 42.95 16.60 17 26857 1721 90599852
Lymphadenopathy 42.79 16.60 60 26814 45715 90555858
Jarisch-Herxheimer reaction 42.50 16.60 12 26862 424 90601149
Headache 41.63 16.60 125 26749 862621 89738952
Irritable bowel syndrome 41.61 16.60 6 26868 207442 90394131
Hepatitis fulminant 40.82 16.60 21 26853 3924 90597649
Distributive shock 40.63 16.60 20 26854 3404 90598169
Swelling 40.20 16.60 39 26835 419019 90182554
Type I hypersensitivity 39.79 16.60 21 26853 4134 90597439
Unintended pregnancy 39.73 16.60 26 26848 7611 90593962
Intentional product use issue 39.70 16.60 8 26866 216884 90384689
Granuloma 39.56 16.60 24 26850 6161 90595412
Stomatitis 39.50 16.60 16 26858 274682 90326891
Hepatitis cholestatic 39.38 16.60 27 26847 8534 90593039
Constipation 39.24 16.60 17 26857 280378 90321195
Focal dyscognitive seizures 39.22 16.60 19 26855 3125 90598448
Lower respiratory tract infection 38.73 16.60 13 26861 250646 90350927
Pulmonary toxicity 38.59 16.60 30 26844 11501 90590072
Blood creatine phosphokinase increased 38.56 16.60 49 26825 33974 90567599
Oedematous kidney 38.48 16.60 9 26865 147 90601426
Rash morbilliform 37.56 16.60 20 26854 4009 90597564
Abdominal discomfort 36.63 16.60 53 26821 477275 90124298
Adrenocortical insufficiency acute 36.36 16.60 17 26857 2584 90598989
Urinary tract infection 36.18 16.60 23 26851 305609 90295964
Ill-defined disorder 35.60 16.60 6 26868 184885 90416688
Oedematous pancreatitis 35.55 16.60 12 26862 773 90600800
Acute respiratory distress syndrome 35.21 16.60 43 26831 28643 90572930
Hydrocephalus 34.80 16.60 22 26852 6072 90595501
Aspartate aminotransferase increased 34.71 16.60 87 26787 102850 90498723
Rheumatoid factor positive 34.34 16.60 5 26869 171645 90429928
Wheezing 34.01 16.60 14 26860 238066 90363507
Leukopenia 33.83 16.60 85 26789 100625 90500948
Alanine aminotransferase increased 33.78 16.60 94 26780 118244 90483329
Coagulopathy 33.72 16.60 38 26836 23251 90578322
Neutropenia 33.65 16.60 144 26730 224760 90376813
Tubo-ovarian abscess 33.44 16.60 10 26864 434 90601139
Memory impairment 32.69 16.60 9 26865 197235 90404338
Generalised onset non-motor seizure 32.34 16.60 6 26868 28 90601545
Toxic skin eruption 32.32 16.60 31 26843 15743 90585830
Linear IgA disease 32.21 16.60 15 26859 2259 90599314
Skin odour abnormal 32.01 16.60 14 26860 1821 90599752
Weight increased 31.47 16.60 47 26827 417880 90183693
Eosinophil count increased 31.24 16.60 28 26846 13053 90588520
Therapy naive 31.22 16.60 6 26868 35 90601538
Muscle spasms 31.14 16.60 18 26856 251865 90349708
Chromaturia 30.71 16.60 33 26841 19154 90582419
Product dose omission issue 30.53 16.60 25 26849 291662 90309911
Disease progression 30.51 16.60 109 26765 156506 90445067
Osteoarthritis 30.50 16.60 10 26864 195720 90405853
Acid fast bacilli infection 30.43 16.60 7 26867 106 90601467
Haemolytic anaemia 29.85 16.60 26 26848 11671 90589902
Vogt-Koyanagi-Harada disease 29.78 16.60 9 26865 405 90601168
Meningitis tuberculous 29.56 16.60 10 26864 648 90600925
Joint range of motion decreased 29.46 16.60 3 26871 135640 90465933
Disseminated intravascular coagulation 29.25 16.60 34 26840 21504 90580069
Migraine 29.19 16.60 10 26864 190382 90411191
Respiratory symptom 28.49 16.60 17 26857 4235 90597338
Blood alkaline phosphatase increased 28.29 16.60 51 26823 48028 90553545
Premature delivery 27.93 16.60 45 26829 38717 90562856
Cholestatic liver injury 27.59 16.60 16 26858 3781 90597792
Diabetes insipidus 27.31 16.60 15 26859 3197 90598376
Product prescribing issue 27.22 16.60 21 26853 7958 90593615
Atypical mycobacterium test positive 27.19 16.60 5 26869 22 90601551
Encephalopathy 26.99 16.60 49 26825 46395 90555178
Staphylococcal infection 26.75 16.60 50 26824 48389 90553184
Death 26.66 16.60 60 26814 456491 90145082
Dermatitis exfoliative generalised 26.58 16.60 18 26856 5575 90595998
Anuria 26.43 16.60 27 26847 14791 90586782
Skin reaction 26.40 16.60 30 26844 18523 90583050
Asthma 26.29 16.60 20 26854 242140 90359433
Palmoplantar pustulosis 26.29 16.60 9 26865 605 90600968
Infection 26.03 16.60 42 26832 362052 90239521
Haemolysis 26.03 16.60 21 26853 8489 90593084
Rhabdomyolysis 25.96 16.60 51 26823 51205 90550368
Glomerular filtration rate abnormal 25.89 16.60 11 26863 1334 90600239
Dizziness 25.83 16.60 89 26785 589195 90012378
Alagille syndrome 25.72 16.60 4 26870 4 90601569
Skin lesion 25.06 16.60 42 26832 37323 90564250
Premature labour 25 16.60 25 26849 13351 90588222
Eosinophilic pneumonia acute 24.95 16.60 9 26865 706 90600867
Pigment nephropathy 24.87 16.60 5 26869 38 90601535
Mycobacterium abscessus infection 24.78 16.60 10 26864 1065 90600508
Shunt infection 24.37 16.60 6 26868 123 90601450
Mycobacterium test positive 24.35 16.60 7 26867 264 90601309
Purpura non-thrombocytopenic 24.23 16.60 6 26868 126 90601447
Visual acuity reduced 23.86 16.60 32 26842 23378 90578195
Bursitis 23.79 16.60 5 26869 131649 90469924
Lymph node tuberculosis 23.71 16.60 9 26865 814 90600759
Immune system disorder 23.64 16.60 23 26851 11882 90589691
Bronchiectasis 23.49 16.60 31 26843 22299 90579274
Crystalluria 23.14 16.60 8 26866 554 90601019
Erythema multiforme 23.09 16.60 23 26851 12223 90589350
Blood bilirubin increased 22.93 16.60 44 26830 43426 90558147
Type 1 lepra reaction 22.71 16.60 4 26870 13 90601560
Acute generalised exanthematous pustulosis 22.70 16.60 24 26850 13679 90587894
Hepatitis toxic 22.66 16.60 14 26860 3711 90597862
Mastitis bacterial 22.59 16.60 5 26869 63 90601510
Rebound effect 22.24 16.60 20 26854 9364 90592209
Mobility decreased 22.15 16.60 25 26849 250709 90350864
Chest pain 22.11 16.60 38 26836 319607 90281966
Exfoliative rash 22.01 16.60 13 26861 3179 90598394
Breast discomfort 21.98 16.60 8 26866 644 90600929
Pulmonary fibrosis 21.80 16.60 3 26871 107500 90494073
Nephritic syndrome 21.55 16.60 7 26867 400 90601173
Limbal swelling 21.50 16.60 4 26870 19 90601554
Epstein-Barr virus test positive 21.41 16.60 8 26866 693 90600880
Drug level below therapeutic 21.38 16.60 16 26858 5798 90595775
Tear discolouration 21.37 16.60 3 26871 0 90601573
Anxiety 21.27 16.60 37 26837 309735 90291838
Human herpesvirus 6 infection 21.14 16.60 13 26861 3419 90598154
Anticoagulation drug level below therapeutic 21.09 16.60 8 26866 723 90600850
Granulomatous lymphadenitis 20.85 16.60 6 26868 227 90601346
Bullous haemorrhagic dermatosis 20.63 16.60 6 26868 236 90601337
Clostridium difficile colitis 20.62 16.60 32 26842 26674 90574899
Gastrooesophageal reflux disease 20.39 16.60 12 26862 166325 90435248
Hypersensitivity 20.37 16.60 68 26806 454609 90146964
Nystagmus 20.35 16.60 17 26857 7210 90594363
Vomiting 20.23 16.60 337 26537 787956 89813617
Disseminated aspergillosis 20.22 16.60 7 26867 487 90601086
Dyspnoea 20.13 16.60 166 26708 880789 89720784
Hepatosplenomegaly 20.08 16.60 12 26862 2997 90598576
Arthralgia 20.00 16.60 142 26732 778380 89823193
Amnesia 19.85 16.60 4 26870 108501 90493072
Splenic abscess 19.81 16.60 6 26868 272 90601301
Cytomegalovirus chorioretinitis 19.75 16.60 11 26863 2408 90599165
Depression 19.66 16.60 37 26837 300564 90301009
Lactic acidosis 19.53 16.60 45 26829 50418 90551155
Purpura 19.52 16.60 23 26851 14755 90586818
Pancreatitis 19.46 16.60 55 26819 69771 90531802
Tuberculosis of eye 19.40 16.60 4 26870 35 90601538
White matter lesion 19.33 16.60 11 26863 2510 90599063
Vanishing bile duct syndrome 19.28 16.60 9 26865 1363 90600210
Nosocomial infection 19.26 16.60 10 26864 1903 90599670
Neck pain 19.26 16.60 5 26869 113958 90487615
Back pain 19.06 16.60 41 26833 317134 90284439
Skin hyperpigmentation 19.06 16.60 16 26858 6835 90594738
Tinea capitis 19.01 16.60 4 26870 39 90601534
Wound secretion 18.94 16.60 14 26860 4976 90596597
Pneumonia lipoid 18.86 16.60 5 26869 139 90601434
Musculoskeletal pain 18.77 16.60 14 26860 171237 90430336
Drug intolerance 18.73 16.60 209 26665 447382 90154191
Cryptococcosis 18.68 16.60 9 26865 1462 90600111
Enterovirus infection 18.66 16.60 9 26865 1465 90600108
Mycobacterium ulcerans infection 18.65 16.60 4 26870 43 90601530
Abdominal lymphadenopathy 18.54 16.60 8 26866 1007 90600566
Endocarditis 18.53 16.60 16 26858 7097 90594476
Psychiatric symptom 18.52 16.60 16 26858 7102 90594471
Insomnia 18.51 16.60 45 26829 333429 90268144
Gamma-glutamyltransferase increased 18.30 16.60 37 26837 37915 90563658
Post treatment Lyme disease syndrome 18.08 16.60 3 26871 6 90601567
Hepatic necrosis 17.83 16.60 15 26859 6423 90595150
Labelled drug-drug interaction issue 17.71 16.60 10 26864 2248 90599325
Injection site reaction 17.69 16.60 3 26871 92077 90509496
Mixed liver injury 17.58 16.60 16 26858 7607 90593966
Encephalitis 17.56 16.60 19 26855 11115 90590458
Hospitalisation 17.54 16.60 8 26866 128092 90473481
Shock 17.53 16.60 31 26843 28747 90572826
Antipsychotic drug level decreased 17.47 16.60 6 26868 407 90601166
Coagulation factor deficiency 17.42 16.60 4 26870 60 90601513
Bronchitis 17.42 16.60 12 26862 152915 90448658
Musculoskeletal stiffness 17.27 16.60 39 26835 296493 90305080
Bile duct necrosis 17.22 16.60 3 26871 9 90601564
Ophthalmoplegia 17.20 16.60 9 26865 1740 90599833
Nephropathy toxic 17.18 16.60 20 26854 12668 90588905
Folate deficiency 17.02 16.60 11 26863 3154 90598419
Blister 17.01 16.60 31 26843 254967 90346606
Eyelid oedema 17.01 16.60 19 26855 11515 90590058
Neurotoxicity 16.96 16.60 26 26848 21441 90580132
Fluid retention 16.64 16.60 3 26871 88088 90513485

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Paradoxical drug reaction 1289.66 15.61 347 28002 4391 42588595
Drug reaction with eosinophilia and systemic symptoms 1123.85 15.61 551 27798 41524 42551462
Drug-induced liver injury 466.83 15.61 300 28049 37973 42555013
Drug resistance 466.71 15.61 288 28061 33960 42559026
Drug interaction 452.35 15.61 707 27642 266292 42326694
Immune reconstitution inflammatory syndrome 444.88 15.61 188 28161 9955 42583031
Eosinophilia 282.88 15.61 208 28141 32691 42560295
Type 2 lepra reaction 278.11 15.61 61 28288 294 42592692
Hepatotoxicity 269.52 15.61 182 28167 24985 42568001
Jaundice 251.74 15.61 198 28151 34391 42558595
Immune reconstitution inflammatory syndrome associated tuberculosis 233.10 15.61 58 28291 523 42592463
Rash maculo-papular 217.13 15.61 188 28161 37315 42555671
Drug level decreased 183.51 15.61 102 28247 9875 42583111
Drug ineffective 180.72 15.61 860 27489 629337 41963649
Mycobacterium avium complex infection 142.36 15.61 59 28290 2968 42590018
Tuberculosis 140.10 15.61 86 28263 10013 42582973
Mycobacterial infection 135.68 15.61 55 28294 2613 42590373
Acute kidney injury 134.14 15.61 540 27809 366797 42226189
Hypoprothrombinaemia 125.34 15.61 34 28315 442 42592544
Condition aggravated 124.20 15.61 418 27931 260336 42332650
Cholestasis 123.80 15.61 130 28219 32749 42560237
Hepatocellular injury 123.63 15.61 112 28237 23566 42569420
Treatment failure 122.51 15.61 178 28171 62446 42530540
Optic neuropathy 118.26 15.61 49 28300 2463 42590523
Tubulointerstitial nephritis 113.92 15.61 122 28227 31426 42561560
Thrombocytopenia 112.59 15.61 329 28020 189950 42403036
Cardiac valve vegetation 111.99 15.61 32 28317 509 42592477
Death 101.14 15.61 99 28250 471086 42121900
Hepatitis 97.55 15.61 105 28244 27195 42565791
Vascular purpura 97.39 15.61 41 28308 2145 42590841
Pyrexia 96.79 15.61 516 27833 393526 42199460
Hepatic cytolysis 95.49 15.61 103 28246 26741 42566245
Eosinophilic pneumonia 92.82 15.61 51 28298 4823 42588163
Pathogen resistance 90.75 15.61 69 28280 11381 42581605
Fall 87.38 15.61 24 28325 234496 42358490
Immune system disorder 77.58 15.61 49 28300 5995 42586991
Drug ineffective for unapproved indication 75.79 15.61 121 28228 46042 42546944
Tuberculoma of central nervous system 74.52 15.61 20 28329 249 42592737
Vitamin K deficiency 73.79 15.61 22 28327 409 42592577
Multiple-drug resistance 71.35 15.61 50 28299 7272 42585714
Granuloma 70.72 15.61 40 28309 4001 42588985
Jarisch-Herxheimer reaction 67.87 15.61 24 28325 779 42592207
Dermatitis exfoliative generalised 66.82 15.61 44 28305 5780 42587206
Lymphadenopathy 65.43 15.61 95 28254 33270 42559716
Alveolar lung disease 63.83 15.61 20 28329 442 42592544
Hepatic failure 62.71 15.61 100 28249 38000 42554986
Fatigue 61.86 15.61 123 28226 435518 42157468
Febrile neutropenia 60.37 15.61 24 28325 185679 42407307
Pulmonary tuberculosis 59.35 15.61 40 28309 5461 42587525
Mycobacterium abscessus infection 57.77 15.61 21 28328 739 42592247
Coagulopathy 56.99 15.61 72 28277 22090 42570896
Acute hepatic failure 56.35 15.61 63 28286 17010 42575976
Pulmonary interstitial emphysema syndrome 55.99 15.61 19 28330 544 42592442
Haemolytic anaemia 54.88 15.61 53 28296 12074 42580912
Constipation 54.37 15.61 20 28329 162271 42430715
Purpura 53.92 15.61 52 28297 11827 42581159
Hydrocephalus 53.46 15.61 39 28310 6039 42586947
Liver function test abnormal 53.28 15.61 85 28264 32306 42560680
Hidradenitis 52.97 15.61 25 28324 1716 42591270
Completed suicide 52.04 15.61 3 28346 96462 42496524
Pneumonia 51.86 15.61 129 28220 422020 42170966
Ototoxicity 51.78 15.61 27 28322 2298 42590688
Type IV hypersensitivity reaction 50.58 15.61 27 28322 2410 42590576
Hepatic function abnormal 50.27 15.61 108 28241 51459 42541527
Tuberculosis of central nervous system 49.63 15.61 14 28335 212 42592774
Myocardial infarction 49.41 15.61 11 28338 123998 42468988
Immunosuppressant drug level decreased 48.86 15.61 24 28325 1800 42591186
Meningitis tuberculous 48.79 15.61 18 28331 661 42592325
Product dose omission issue 48.46 15.61 21 28328 154344 42438642
Pain 48.36 15.61 55 28294 244793 42348193
Optic neuritis 46.81 15.61 31 28318 4111 42588875
Vascular pseudoaneurysm thrombosis 46.78 15.61 11 28338 76 42592910
Drug abuse 46.67 15.61 7 28342 104764 42488222
Hypovitaminosis 46.23 15.61 18 28331 768 42592218
Dizziness 46.03 15.61 59 28290 249195 42343791
Product use in unapproved indication 45.33 15.61 242 28107 184214 42408772
Tuberculosis of eye 45.28 15.61 10 28339 50 42592936
Type 1 lepra reaction 45.28 15.61 10 28339 50 42592936
Infective aneurysm 44.31 15.61 19 28330 1040 42591946
Drug eruption 44.21 15.61 65 28284 23010 42569976
Disseminated tuberculosis 44.21 15.61 26 28323 2798 42590188
Toxic skin eruption 44.17 15.61 50 28299 13680 42579306
Hepatic encephalopathy 43.20 15.61 54 28295 16388 42576598
Linear IgA disease 42.81 15.61 23 28326 2080 42590906
Immune thrombocytopenia 41.57 15.61 44 28305 11172 42581814
Mycobacterium tuberculosis complex test positive 40.51 15.61 20 28329 1516 42591470
Malignant neoplasm progression 38.65 15.61 12 28337 108388 42484598
Renal tubular necrosis 38.53 15.61 54 28295 18300 42574686
Hypersensitivity vasculitis 38.41 15.61 25 28324 3219 42589767
Granulomatous liver disease 37.49 15.61 15 28334 688 42592298
Skin disorder 37.29 15.61 51 28298 16893 42576093
Hepatitis cholestatic 37.23 15.61 39 28310 9785 42583201
Anticoagulation drug level decreased 37.22 15.61 11 28338 198 42592788
Diaphragmatic injury 37.15 15.61 10 28339 126 42592860
Hyperbilirubinaemia 36.50 15.61 56 28293 20579 42572407
Atrial fibrillation 36.46 15.61 24 28325 139569 42453417
Anxiety 35.84 15.61 17 28332 118543 42474443
Diffuse alveolar damage 35.75 15.61 22 28327 2570 42590416
Oliguria 35.34 15.61 37 28312 9276 42583710
Cardiac failure congestive 35.31 15.61 7 28342 85595 42507391
Thalamic infarction 35.11 15.61 15 28334 814 42592172
Rash morbilliform 35.07 15.61 26 28323 4127 42588859
Diarrhoea 34.89 15.61 173 28176 460676 42132310
Ocular toxicity 34.52 15.61 12 28337 370 42592616
Brain abscess 34.34 15.61 26 28323 4258 42588728
Lymph node tuberculosis 34.33 15.61 13 28336 514 42592472
Atypical mycobacterial infection 33.71 15.61 17 28332 1349 42591637
Adrenocortical insufficiency acute 33.64 15.61 20 28329 2195 42590791
Blood pressure increased 33.38 15.61 13 28336 101915 42491071
Transaminases increased 33.34 15.61 70 28279 32815 42560171
Nasopharyngitis 32.36 15.61 8 28341 83988 42508998
Eosinophilic pneumonia acute 32.03 15.61 14 28335 803 42592183
Atypical mycobacterium test positive 31.68 15.61 8 28341 77 42592909
Aortic valve prolapse 31.66 15.61 6 28343 11 42592975
Pulmonary cavitation 31.51 15.61 16 28333 1288 42591698
Labelled drug-drug interaction medication error 31.46 15.61 45 28304 15537 42577449
Preterm premature rupture of membranes 31.22 15.61 8 28341 82 42592904
Urinary tract inflammation 31.21 15.61 10 28339 238 42592748
Hypertransaminasaemia 30.36 15.61 34 28315 9193 42583793
Toxic epidermal necrolysis 29.55 15.61 59 28290 26691 42566295
Unmasking of previously unidentified disease 29.47 15.61 15 28334 1214 42591772
Splenic embolism 29.38 15.61 10 28339 289 42592697
Accelerated hypertension 29.25 15.61 10 28339 293 42592693
Malaise 29.07 15.61 61 28288 212095 42380891
Dehydration 28.88 15.61 31 28318 141736 42451250
Dyspnoea 28.63 15.61 175 28174 442446 42150540
Bone tuberculosis 28.51 15.61 11 28338 458 42592528
Drug intolerance 28.13 15.61 117 28232 80307 42512679
Tendon disorder 28.13 15.61 21 28328 3368 42589618
Asthma 28.12 15.61 4 28345 62310 42530676
Tuberculoid leprosy 28.04 15.61 7 28342 64 42592922
Injection site pain 27.81 15.61 3 28346 57795 42535191
Encephalopathy 27.80 15.61 75 28274 41258 42551728
Cross sensitivity reaction 27.75 15.61 16 28333 1659 42591327
Hyperammonaemia 27.64 15.61 30 28319 7836 42585150
Sideroblastic anaemia 27.37 15.61 10 28339 357 42592629
Cutaneous vasculitis 27.37 15.61 28 28321 6832 42586154
Vitamin B1 decreased 26.86 15.61 10 28339 377 42592609
Depression 26.65 15.61 21 28328 111342 42481644
Pigment nephropathy 26.54 15.61 6 28343 34 42592952
Muscle spasms 26.52 15.61 12 28337 86032 42506954
Vasculitis necrotising 26.46 15.61 13 28336 975 42592011
Generalised oedema 26.25 15.61 41 28308 15295 42577691
Hepatic necrosis 25.46 15.61 21 28328 3892 42589094
Petechiae 25.40 15.61 33 28316 10402 42582584
Central nervous system vasculitis 25.30 15.61 11 28338 623 42592363
Pericarditis lupus 25.27 15.61 4 28345 0 42592986
Endocarditis 25.06 15.61 29 28320 8123 42584863
Infusion related reaction 25.01 15.61 5 28344 60801 42532185
White blood cell count decreased 24.96 15.61 22 28327 110374 42482612
Embolic cerebral infarction 24.72 15.61 12 28337 877 42592109
Bradycardia 24.71 15.61 13 28336 85471 42507515
Neutropenia 24.60 15.61 221 28128 199210 42393776
Shock haemorrhagic 24.50 15.61 41 28308 16201 42576785
Feeling abnormal 24.38 15.61 8 28341 69778 42523208
Skin hyperpigmentation 24.24 15.61 21 28328 4160 42588826
Coagulation factor X level decreased 24.19 15.61 5 28344 17 42592969
Hypotension 24.17 15.61 89 28260 257542 42335444
Henoch-Schonlein purpura 24.07 15.61 16 28333 2134 42590852
Leukopenia 24.03 15.61 106 28243 74640 42518346
Hepatic enzyme increased 24.00 15.61 76 28273 45708 42547278
Insomnia 23.92 15.61 26 28323 118227 42474759
Influenza 23.79 15.61 6 28343 62169 42530817
Deafness 23.72 15.61 36 28313 13104 42579882
Cerebrovascular accident 23.66 15.61 18 28331 97142 42495844
Liver injury 23.30 15.61 44 28305 19104 42573882
Coronary artery disease 22.99 15.61 4 28345 53716 42539270
Weight increased 22.68 15.61 23 28326 107960 42485026
Choroiditis 22.42 15.61 13 28336 1362 42591624
Interferon gamma release assay positive 22.41 15.61 7 28342 153 42592833
Autoimmune haemolytic anaemia 22.36 15.61 23 28326 5648 42587338
Syncope 22.24 15.61 20 28329 99386 42493600
Tuberculous pleurisy 22.09 15.61 9 28340 433 42592553
Lymphopenia 21.97 15.61 46 28303 21517 42571469
Pneumatosis intestinalis 21.93 15.61 21 28328 4731 42588255
Dermatitis exfoliative 21.84 15.61 25 28324 6922 42586064
Hypermetabolism 21.84 15.61 8 28341 288 42592698
Disseminated Bacillus Calmette-Guerin infection 21.76 15.61 8 28341 291 42592695
Hepatic haemorrhage 21.63 15.61 10 28339 655 42592331
Plasma cell myeloma 21.59 15.61 3 28346 47575 42545411
Drug level abnormal 21.55 15.61 8 28341 299 42592687
Asthenia 21.42 15.61 105 28244 280688 42312298
Drug level below therapeutic 21.33 15.61 24 28325 6521 42586465
Lichenoid keratosis 21.22 15.61 19 28330 3931 42589055
Haemophagocytic lymphohistiocytosis 21.10 15.61 41 28308 18181 42574805
Wound drainage 20.95 15.61 10 28339 704 42592282
Memory impairment 20.93 15.61 4 28345 50218 42542768
Optic atrophy 20.88 15.61 12 28337 1237 42591749
Conductive deafness 20.73 15.61 9 28340 508 42592478
Somnolence 20.66 15.61 39 28310 141066 42451920
Hyperglycaemia 20.56 15.61 3 28346 45856 42547130
Thrombocytopenic purpura 20.53 15.61 12 28337 1277 42591709
Cat scratch disease 20.36 15.61 8 28341 350 42592636
Jaundice cholestatic 20.16 15.61 21 28328 5232 42587754
Pulmonary granuloma 20.04 15.61 13 28336 1664 42591322
Agranulocytosis 20.04 15.61 55 28294 30557 42562429
Fixed eruption 19.91 15.61 15 28334 2439 42590547
Blood pressure decreased 19.83 15.61 7 28342 58325 42534661
Acute myocardial infarction 19.74 15.61 7 28342 58158 42534828
Type III immune complex mediated reaction 19.71 15.61 9 28340 573 42592413
Intentional overdose 19.62 15.61 5 28344 51451 42541535
Liver transplant rejection 19.59 15.61 15 28334 2498 42590488
Antimicrobial susceptibility test resistant 19.57 15.61 8 28341 388 42592598
Stress 19.57 15.61 3 28346 44209 42548777
Acid fast bacilli infection 19.48 15.61 6 28343 125 42592861
Leprosy 19.39 15.61 6 28343 127 42592859
Encephalitis 19.30 15.61 27 28322 9131 42583855
Staphylococcal infection 19.28 15.61 62 28287 37581 42555405
Pulmonary sequestration 19.28 15.61 5 28344 54 42592932
Tuberculosis gastrointestinal 19.19 15.61 7 28342 249 42592737
Implant site infection 18.99 15.61 11 28338 1150 42591836
Stevens-Johnson syndrome 18.85 15.61 44 28305 22134 42570852
Prothrombin level decreased 18.78 15.61 11 28338 1175 42591811
Splenic abscess 18.65 15.61 9 28340 649 42592337
Pulmonary eosinophilia 18.53 15.61 7 28342 275 42592711
Pain in extremity 18.43 15.61 46 28303 150558 42442428
Inappropriate schedule of product administration 18.40 15.61 22 28327 95880 42497106
Rash 18.35 15.61 272 28077 276682 42316304
C-reactive protein increased 18.10 15.61 87 28262 63473 42529513
Dilatation intrahepatic duct acquired 18.09 15.61 5 28344 70 42592916
Loss of consciousness 17.92 15.61 21 28328 92333 42500653
Hepatorenal syndrome 17.91 15.61 15 28334 2839 42590147
Donor leukocyte infusion 17.77 15.61 5 28344 75 42592911
Fistula 17.69 15.61 24 28325 7888 42585098
Prostate cancer 17.69 15.61 4 28345 44639 42548347
Inflammation 17.56 15.61 56 28293 33791 42559195
Blood glucose increased 17.50 15.61 14 28335 73685 42519301
Malabsorption from administration site 17.35 15.61 5 28344 82 42592904
Bronchitis 17.22 15.61 5 28344 47196 42545790
Dysbiosis 16.98 15.61 9 28340 792 42592194
CD4/CD8 ratio decreased 16.97 15.61 4 28345 28 42592958
Nocardiosis 16.86 15.61 19 28330 5171 42587815
Headache 16.84 15.61 92 28257 239277 42353709
Iridocyclitis 16.80 15.61 13 28336 2198 42590788
Tremor 16.78 15.61 24 28325 96905 42496081
Urinary tract infection 16.78 15.61 25 28324 99259 42493727
Mucosal inflammation 16.65 15.61 6 28343 49368 42543618
Trisomy 21 16.62 15.61 8 28341 574 42592412
Lupus-like syndrome 16.61 15.61 15 28334 3139 42589847
Treatment noncompliance 16.60 15.61 59 28290 37613 42555373
Psoas abscess 16.50 15.61 9 28340 838 42592148
Cardiac disorder 16.41 15.61 6 28343 48926 42544060
Hemianopia heteronymous 16.28 15.61 4 28345 34 42592952
Oral candidiasis 16.18 15.61 32 28317 14373 42578613
Off label use 16.17 15.61 546 27803 637789 41955197
Skin lesion 16.01 15.61 47 28302 27127 42565859
Peripheral swelling 15.98 15.61 22 28327 90248 42502738
Protrusion tongue 15.85 15.61 6 28343 237 42592749
Axonal neuropathy 15.82 15.61 10 28339 1225 42591761
Lower respiratory tract infection 15.72 15.61 4 28345 41202 42551784
Splenic infarction 15.72 15.61 13 28336 2418 42590568
Hypersensitivity pneumonitis 15.71 15.61 12 28337 1992 42590994
Platelet count decreased 15.68 15.61 44 28305 138537 42454449
Gastrointestinal disorder 15.63 15.61 67 28282 46586 42546400

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Drug reaction with eosinophilia and systemic symptoms 2786.49 14.08 1141 50244 80954 110456960
Paradoxical drug reaction 2021.39 14.08 535 50850 9282 110528632
Drug interaction 1173.03 14.08 1295 50090 498888 110039026
Drug resistance 829.21 14.08 440 50945 55934 110481980
Drug-induced liver injury 753.01 14.08 544 50841 119523 110418391
Immune reconstitution inflammatory syndrome 722.31 14.08 275 51110 15951 110521963
Eosinophilia 691.53 14.08 394 50991 57542 110480372
Jaundice 510.69 14.08 327 51058 58909 110479005
Rash maculo-papular 450.65 14.08 330 51055 73892 110464022
Immune reconstitution inflammatory syndrome associated tuberculosis 427.18 14.08 99 51286 955 110536959
Hepatotoxicity 410.21 14.08 293 51092 63107 110474807
Acute kidney injury 396.34 14.08 895 50490 634535 109903379
Type 2 lepra reaction 360.60 14.08 73 51312 342 110537572
Drug level decreased 348.79 14.08 171 51214 18377 110519537
Tuberculosis 331.64 14.08 163 51222 17611 110520303
Drug ineffective 325.33 14.08 1478 49907 1519062 109018852
Acute hepatic failure 318.38 14.08 203 51182 36265 110501649
Cholestasis 277.22 14.08 234 51151 64284 110473630
Hepatocellular injury 253.98 14.08 201 51184 50441 110487473
Tuberculoma of central nervous system 239.70 14.08 56 51329 561 110537353
Tubulointerstitial nephritis 209.10 14.08 185 51200 54099 110483815
Thrombocytopenia 208.53 14.08 484 50901 348401 110189513
Pyrexia 207.36 14.08 895 50490 897370 109640544
Hepatic cytolysis 193.12 14.08 178 51207 54875 110483039
Mycobacterium avium complex infection 189.61 14.08 79 51306 5798 110532116
Mycobacterial infection 182.70 14.08 71 51314 4346 110533568
Optic neuropathy 179.04 14.08 71 51314 4587 110533327
Pathogen resistance 173.45 14.08 106 51279 17566 110520348
Hypoprothrombinaemia 167.77 14.08 46 51339 913 110537001
Pneumatosis intestinalis 161.42 14.08 79 51306 8450 110529464
Pulmonary tuberculosis 156.25 14.08 79 51306 9060 110528854
Drug ineffective for unapproved indication 154.90 14.08 214 51171 102624 110435290
Vascular purpura 146.76 14.08 58 51327 3713 110534201
Hepatic failure 139.71 14.08 166 51219 68573 110469341
Fall 134.69 14.08 56 51329 603426 109934488
Optic neuritis 133.37 14.08 76 51309 11071 110526843
Infusion related reaction 133.07 14.08 12 51373 381150 110156764
Hidradenitis 129 14.08 58 51327 5122 110532792
Hepatic encephalopathy 128.61 14.08 106 51279 28150 110509764
Pain 126.51 14.08 155 51230 954800 109583114
Lymphadenopathy 124.55 14.08 151 51234 63684 110474230
Nasopharyngitis 123.74 14.08 18 51367 394343 110143571
Fatigue 122.28 14.08 238 51147 1215720 109322194
Hepatitis 120.29 14.08 177 51208 89877 110448037
Hepatic function abnormal 119.99 14.08 176 51209 89119 110448795
Cardiac valve vegetation 119.68 14.08 36 51349 1004 110536910
Condition aggravated 117.42 14.08 660 50725 734176 109803738
Eosinophilic pneumonia 113.49 14.08 59 51326 7168 110530746
Immune system disorder 110.02 14.08 72 51313 13429 110524485
Granuloma 108.98 14.08 63 51322 9427 110528487
Immunosuppressant drug level decreased 105.67 14.08 42 51343 2729 110535185
Multiple-drug resistance 104.01 14.08 69 51316 13166 110524748
Transaminases increased 103.16 14.08 137 51248 63253 110474661
Jarisch-Herxheimer reaction 101.77 14.08 33 51352 1184 110536730
Disseminated tuberculosis 101.40 14.08 49 51336 5097 110532817
Coagulopathy 98.71 14.08 108 51277 40803 110497111
Dermatitis exfoliative generalised 98.02 14.08 62 51323 10910 110527004
Hyperbilirubinaemia 97.64 14.08 94 51291 30577 110507337
Haemolytic anaemia 96.29 14.08 79 51306 20841 110517073
Hypertransaminasaemia 96.05 14.08 84 51301 24171 110513743
Alopecia 94.94 14.08 26 51359 364727 110173187
Renal tubular necrosis 94.38 14.08 92 51293 30383 110507531
Type IV hypersensitivity reaction 94.02 14.08 49 51336 5984 110531930
Completed suicide 92.16 14.08 5 51380 242376 110295538
Wound 88.63 14.08 5 51380 234432 110303482
Constipation 86.79 14.08 29 51356 357757 110180157
Joint swelling 85.27 14.08 50 51335 442795 110095119
Rheumatoid arthritis 84.54 14.08 18 51367 299595 110238319
Meningitis tuberculous 84.37 14.08 29 51356 1249 110536665
Headache 83.17 14.08 179 51206 882198 109655716
Drug eruption 82.78 14.08 113 51272 53546 110484368
Peripheral swelling 81.56 14.08 43 51342 403991 110133923
Hydrocephalus 81.31 14.08 54 51331 10321 110527593
Anticoagulation drug level decreased 79.87 14.08 20 51365 274 110537640
Arthropathy 79.65 14.08 18 51367 287504 110250410
Product use in unapproved indication 79.51 14.08 414 50971 446963 110090951
Atypical mycobacterial infection 79.23 14.08 34 51351 2684 110535230
Death 78.88 14.08 127 51258 698742 109839172
Labelled drug-drug interaction medication error 77.10 14.08 81 51304 29221 110508693
Dizziness 76.82 14.08 129 51256 698064 109839850
Purpura 76.23 14.08 74 51311 24314 110513600
Linear IgA disease 75.20 14.08 38 51347 4351 110533563
Impaired healing 74.96 14.08 4 51381 196713 110341201
Product dose omission issue 74.75 14.08 28 51357 321754 110216160
Type 1 lepra reaction 74.49 14.08 15 51370 68 110537846
Pemphigus 74.19 14.08 7 51378 214563 110323351
Hepatitis cholestatic 73.94 14.08 63 51322 17503 110520411
Toxic skin eruption 72.29 14.08 76 51309 27439 110510475
Rash morbilliform 71.20 14.08 45 51340 7906 110530008
Choroiditis 70.50 14.08 27 51358 1588 110536326
Multiple organ dysfunction syndrome 70.02 14.08 191 51194 151519 110386395
Pain in extremity 69.84 14.08 74 51311 487044 110050870
Blood cholesterol increased 69.66 14.08 4 51381 184781 110353133
Adrenocortical insufficiency acute 69.01 14.08 36 51349 4404 110533510
Ototoxicity 68.55 14.08 35 51350 4096 110533818
Liver function test abnormal 67.96 14.08 118 51267 68832 110469082
Lower respiratory tract infection 67.77 14.08 15 51370 243091 110294823
Mycobacterium abscessus infection 65.55 14.08 26 51359 1680 110536234
Anti-cyclic citrullinated peptide antibody positive 65.48 14.08 5 51380 181979 110355935
Stomatitis 65.35 14.08 22 51363 270220 110267694
Off label use 65.24 14.08 1017 50368 1499168 109038746
Vitamin K deficiency 65.11 14.08 22 51363 899 110537015
Synovitis 65.10 14.08 23 51362 274069 110263845
Lymph node tuberculosis 64.99 14.08 23 51362 1081 110536833
Asthma 64.81 14.08 18 51367 250273 110287641
Metabolic acidosis 64.56 14.08 143 51242 99601 110438313
Abdominal discomfort 64.49 14.08 53 51332 393805 110144109
Neutropenia 63.32 14.08 342 51043 374278 110163636
Wheezing 63.09 14.08 20 51365 255210 110282704
Dyspnoea 62.77 14.08 283 51102 1106589 109431325
Pulmonary interstitial emphysema syndrome 62.29 14.08 19 51366 556 110537358
Alveolar lung disease 62.18 14.08 20 51365 699 110537215
Contusion 61.90 14.08 16 51369 233345 110304569
Encephalopathy 61.50 14.08 124 51261 80931 110456983
Glomerulonephritis minimal lesion 61.46 14.08 22 51363 1069 110536845
Agranulocytosis 61.26 14.08 106 51279 61654 110476260
Treatment failure 61.07 14.08 273 51112 276961 110260953
Systemic lupus erythematosus 60.99 14.08 21 51364 254317 110283597
Injury 60.71 14.08 6 51379 177259 110360655
Type 2 diabetes mellitus 60.69 14.08 6 51379 177226 110360688
Muscle spasms 60.07 14.08 27 51358 278130 110259784
Leukopenia 59.59 14.08 178 51207 148613 110389301
Memory impairment 59.44 14.08 10 51375 196934 110340980
Pancytopenia 58.45 14.08 222 51163 209391 110328523
Drug abuse 58.23 14.08 7 51378 177404 110360510
Irritable bowel syndrome 57.73 14.08 5 51380 164210 110373704
Anxiety 57.03 14.08 46 51339 345032 110192882
Intentional product use issue 56.85 14.08 22 51363 247884 110290030
Pneumonia 56.62 14.08 213 51172 876501 109661413
Eosinophilic pneumonia acute 55.80 14.08 23 51362 1642 110536272
Renal impairment 55.39 14.08 203 51182 188242 110349672
Infective aneurysm 54.76 14.08 22 51363 1470 110536444
Discomfort 54.55 14.08 16 51369 214691 110323223
Pericarditis 54.45 14.08 17 51368 219097 110318817
Febrile neutropenia 53.89 14.08 41 51344 316726 110221188
Psoriatic arthropathy 53.13 14.08 13 51372 196748 110341166
Pulmonary cavitation 52.84 14.08 24 51361 2170 110535744
Brain abscess 52.46 14.08 35 51350 6739 110531175
Weight increased 52.41 14.08 71 51314 419573 110118341
Urinary tract infection 52.06 14.08 45 51340 326237 110211677
Pigment nephropathy 52.05 14.08 11 51374 66 110537848
Pancreatitis haemorrhagic 51.68 14.08 19 51366 997 110536917
Status epilepticus 50.99 14.08 68 51317 31503 110506411
Tuberculosis of central nervous system 50.83 14.08 16 51369 521 110537393
Insomnia 50.30 14.08 56 51329 360534 110177380
Vascular pseudoaneurysm thrombosis 50.22 14.08 11 51374 80 110537834
Ocular toxicity 50.05 14.08 20 51365 1318 110536596
Tuberculosis of eye 49.75 14.08 11 51374 84 110537830
Tuberculosis gastrointestinal 48.67 14.08 16 51369 600 110537314
Malignant neoplasm progression 48.18 14.08 11 51374 174556 110363358
Pregnancy with implant contraceptive 47.99 14.08 23 51362 2349 110535565
Contraindicated product administered 47.79 14.08 28 51357 248239 110289675
Drug level below therapeutic 47.37 14.08 41 51344 11632 110526282
Latent tuberculosis 47.26 14.08 27 51358 3950 110533964
Ill-defined disorder 47.25 14.08 8 51377 156845 110381069
Mobility decreased 46.81 14.08 26 51359 237396 110300518
Immune thrombocytopenia 46.80 14.08 55 51330 22439 110515475
Mycobacterium tuberculosis complex test positive 46.41 14.08 25 51360 3263 110534651
Osteoarthritis 45.68 14.08 14 51371 182609 110355305
Migraine 45.07 14.08 12 51373 171640 110366274
Arthralgia 44.31 14.08 199 51186 779433 109758481
Cystic fibrosis pancreatic 43.97 14.08 9 51376 45 110537869
Dry mouth 43.80 14.08 19 51366 199929 110337985
Rheumatoid factor positive 43.68 14.08 5 51380 131635 110406279
Granulomatous liver disease 43.51 14.08 19 51366 1565 110536349
Depression 43.47 14.08 50 51335 317285 110220629
Eosinophil count increased 43.00 14.08 51 51334 21007 110516907
C-reactive protein abnormal 42.85 14.08 5 51380 129690 110408224
Oliguria 42.83 14.08 48 51337 18609 110519305
Hepatic necrosis 42.61 14.08 36 51349 9886 110528028
Sleep disorder 41.76 14.08 20 51365 198624 110339290
Hypovitaminosis 41.69 14.08 18 51367 1442 110536472
Mechanical urticaria 41.50 14.08 14 51371 569 110537345
Gastrooesophageal reflux disease 41.21 14.08 16 51369 179960 110357954
Oligoarthritis 41.19 14.08 15 51370 766 110537148
Disseminated intravascular coagulation 41.12 14.08 71 51314 41215 110496699
Methaemoglobinaemia 40.89 14.08 34 51351 9134 110528780
Musculoskeletal pain 40.72 14.08 17 51368 183006 110354908
Face oedema 40.71 14.08 63 51322 33406 110504508
Diaphragmatic injury 40.71 14.08 10 51375 126 110537788
Haemophagocytic lymphohistiocytosis 40.64 14.08 61 51324 31498 110506416
Bursitis 40.54 14.08 6 51379 129912 110408002
Alanine aminotransferase increased 40.46 14.08 181 51204 183592 110354322
Product prescribing issue 40.37 14.08 39 51346 12733 110525181
Hypersensitivity vasculitis 40.15 14.08 30 51355 6907 110531007
Toxic optic neuropathy 39.99 14.08 17 51368 1311 110536603
Skin lesion 39.17 14.08 79 51306 51552 110486362
Influenza 38.77 14.08 15 51370 169086 110368828
Cutaneous vasculitis 38.61 14.08 38 51347 12691 110525223
Bone tuberculosis 38.28 14.08 14 51371 724 110537190
Type I hypersensitivity 37.79 14.08 28 51357 6365 110531549
Splenic abscess 37.59 14.08 15 51370 985 110536929
Bronchitis 37.57 14.08 13 51372 157019 110380895
Distributive shock 37.49 14.08 27 51358 5877 110532037
Asthenia 37.27 14.08 179 51206 688820 109849094
Tuberculoid leprosy 37.04 14.08 9 51376 108 110537806
Swelling 36.59 14.08 67 51318 350974 110186940
Myocardial infarction 36.49 14.08 22 51363 192061 110345853
Chest pain 36.48 14.08 75 51310 376300 110161614
Thalamic infarction 36.43 14.08 16 51369 1336 110536578
Lymphopenia 36.05 14.08 66 51319 40104 110497810
Obesity 35.92 14.08 5 51380 113346 110424568
Stevens-Johnson syndrome 35.86 14.08 72 51313 46829 110491085
Road traffic accident 35.83 14.08 4 51381 107394 110430520
Petechiae 35.80 14.08 49 51336 23268 110514646
Acid fast bacilli infection 35.76 14.08 10 51375 214 110537700
Splenic embolism 35.67 14.08 10 51375 216 110537698
Renal failure 35.66 14.08 203 51182 226371 110311543
Visual acuity reduced 35.60 14.08 58 51327 32115 110505799
Cardiac failure congestive 35.28 14.08 13 51372 150987 110386927
Joint range of motion decreased 35.00 14.08 7 51378 121825 110416089
Autoimmune haemolytic anaemia 34.79 14.08 33 51352 10534 110527380
Dermatitis exfoliative 34.65 14.08 34 51351 11313 110526601
Hepatitis fulminant 34.60 14.08 30 51355 8530 110529384
Blood bilirubin increased 34.38 14.08 95 51290 75877 110462037
Lactic acidosis 34.31 14.08 108 51277 92703 110445211
Cholestatic liver injury 34.25 14.08 28 51357 7348 110530566
Encephalitis 34.21 14.08 43 51342 18796 110519118
Staphylococcal infection 34.21 14.08 90 51295 69854 110468060
Skin hyperpigmentation 34.19 14.08 30 51355 8666 110529248
Diffuse alveolar damage 33.99 14.08 22 51363 4025 110533889
Nephropathy toxic 33.81 14.08 52 51333 27426 110510488
Henoch-Schonlein purpura 33.50 14.08 21 51364 3636 110534278
Endocarditis 33.47 14.08 36 51349 13335 110524579
Crystalluria 33.19 14.08 15 51370 1340 110536574
Aortic valve prolapse 32.83 14.08 6 51379 14 110537900
Sideroblastic anaemia 32.83 14.08 11 51374 438 110537476
Unmasking of previously unidentified disease 32.82 14.08 19 51366 2849 110535065
Hypoaesthesia 32.72 14.08 60 51325 314163 110223751
Back pain 32.62 14.08 78 51307 370918 110166996
Aspartate aminotransferase increased 32.59 14.08 154 51231 159782 110378132
Hypersensitivity 32.39 14.08 89 51296 403909 110134005
Liver transplant rejection 32.18 14.08 21 51364 3897 110534017
Toxic epidermal necrolysis 31.93 14.08 77 51308 56650 110481264
Skin disorder 31.77 14.08 65 51320 42848 110495066
Thrombosis 31.73 14.08 6 51379 108656 110429258
Intentional overdose 31.65 14.08 11 51374 132490 110405424
Injection site pain 31.58 14.08 22 51363 177900 110360014
Exfoliative rash 31.55 14.08 22 51363 4552 110533362
Liver transplant 31.48 14.08 22 51363 4567 110533347
Feeling abnormal 31.22 14.08 23 51362 180688 110357226
Infection 31.17 14.08 77 51308 362123 110175791
Blood pressure increased 30.95 14.08 45 51340 258328 110279586
Jaundice cholestatic 30.86 14.08 36 51349 14572 110523342
Treatment noncompliance 30.81 14.08 89 51296 72901 110465013
Injection site reaction 30.53 14.08 3 51382 89067 110448847
Musculoskeletal stiffness 30.42 14.08 52 51333 279770 110258144
Oedematous pancreatitis 30.34 14.08 15 51370 1639 110536275
Central nervous system vasculitis 30.34 14.08 15 51370 1639 110536275
Fluid retention 30.26 14.08 4 51381 94303 110443611
Injection site erythema 30.20 14.08 4 51381 94172 110443742
Accelerated hypertension 30.11 14.08 12 51373 785 110537129
Urinary tract inflammation 30.09 14.08 10 51375 388 110537526
Malaise 30.01 14.08 186 51199 671633 109866281
Tubo-ovarian abscess 29.70 14.08 10 51375 404 110537510
Oedematous kidney 29.58 14.08 9 51376 261 110537653
Generalised oedema 29.53 14.08 52 51333 30652 110507262
Aspergillus infection 29.47 14.08 47 51338 25569 110512345
Diarrhoea 29.34 14.08 364 51021 1139141 109398773
Interferon gamma release assay positive 28.61 14.08 8 51377 171 110537743
Hepatitis toxic 28.60 14.08 23 51362 5898 110532016
Staphylococcal bacteraemia 28.58 14.08 37 51348 16651 110521263
Hypertension 28.45 14.08 131 51254 509953 110027961
Conductive deafness 28.42 14.08 9 51376 299 110537615
Septic embolus 28.20 14.08 16 51369 2310 110535604
Muscular weakness 28.10 14.08 45 51340 248423 110289491
Acute generalised exanthematous pustulosis 28.07 14.08 42 51343 21622 110516292
Focal dyscognitive seizures 27.69 14.08 19 51366 3830 110534084
Syncope 27.63 14.08 32 51353 202504 110335410
Mixed liver injury 27.60 14.08 31 51354 12048 110525866
Dyspepsia 27.34 14.08 29 51356 190936 110346978
Pulmonary eosinophilia 27.13 14.08 11 51374 753 110537161
Inappropriate schedule of product administration 26.90 14.08 33 51352 203604 110334310
Dehydration 26.82 14.08 56 51329 279455 110258459
Deafness 26.69 14.08 46 51339 26663 110511251
Acute respiratory distress syndrome 26.57 14.08 69 51316 53129 110484785
Amnesia 26.50 14.08 8 51377 105400 110432514
Antipsychotic drug level decreased 26.48 14.08 13 51372 1399 110536515
Rash 25.98 14.08 530 50855 820434 109717480
Cachexia 25.74 14.08 31 51354 12974 110524940
Hypermetabolism 25.71 14.08 10 51375 613 110537301
Mycobacterium test positive 25.44 14.08 10 51375 631 110537283
Cerebrovascular accident 25.43 14.08 28 51357 181256 110356658
Lichenoid keratosis 25.30 14.08 22 51363 6280 110531634
Pancreatitis 25.18 14.08 98 51287 93435 110444479
Vasculitis necrotising 25.07 14.08 13 51372 1570 110536344
Upper respiratory tract infection 24.99 14.08 15 51370 131313 110406601
Granulomatous lymphadenitis 24.93 14.08 9 51376 448 110537466
Chromaturia 24.79 14.08 47 51338 29313 110508601
Therapy naive 24.77 14.08 6 51379 71 110537843
Loss of personal independence in daily activities 24.76 14.08 20 51365 150000 110387914
Shock haemorrhagic 24.74 14.08 45 51340 27202 110510712
Lower limb fracture 24.65 14.08 3 51382 75345 110462569
Disease recurrence 24.58 14.08 73 51312 60711 110477203
Tuberculous pleurisy 24.50 14.08 10 51375 696 110537218
Optic atrophy 24.42 14.08 15 51370 2506 110535408
Splenomegaly 24.23 14.08 42 51343 24456 110513458
Foetal growth restriction 24.20 14.08 16 51369 3034 110534880
Atypical mycobacterium test positive 24.04 14.08 6 51379 81 110537833
Pulmonary sequestration 23.95 14.08 5 51380 28 110537886
Rhabdomyolysis 23.85 14.08 115 51270 120286 110417628
Lymphadenitis 23.73 14.08 20 51365 5473 110532441
Generalised onset non-motor seizure 23.64 14.08 6 51379 87 110537827
Disseminated Bacillus Calmette-Guerin infection 23.56 14.08 8 51377 332 110537582
Neck pain 23.52 14.08 14 51371 123116 110414798
Virologic failure 23.42 14.08 19 51366 4933 110532981
Hemianopia heteronymous 23.39 14.08 6 51379 91 110537823
Splenic infarction 23.30 14.08 18 51367 4356 110533558
Sciatica 23.25 14.08 7 51378 92392 110445522
Stress 23.08 14.08 10 51375 105338 110432576
Bradycardia 22.95 14.08 23 51362 155494 110382420
Transplant rejection 22.85 14.08 41 51344 24526 110513388
Hyperammonaemia 22.82 14.08 30 51355 13702 110524212
Embolic cerebral infarction 22.80 14.08 12 51373 1494 110536420
Joint tuberculosis 22.41 14.08 7 51378 222 110537692
Vogt-Koyanagi-Harada disease 22.32 14.08 9 51376 607 110537307
Labelled drug-drug interaction issue 22.11 14.08 17 51368 4084 110533830
Nasal congestion 22.06 14.08 9 51376 98273 110439641
Drug level increased 21.92 14.08 60 51325 47659 110490255
Palpitations 21.88 14.08 25 51360 159187 110378727
Thrombocytopenic purpura 21.86 14.08 15 51370 3024 110534890
Tendon disorder 21.85 14.08 23 51362 8314 110529600
Vitamin B1 decreased 21.76 14.08 10 51375 929 110536985
Abdominal pain upper 21.70 14.08 86 51299 349025 110188889
Donor leukocyte infusion 21.59 14.08 5 51380 48 110537866
Neuropathy peripheral 21.57 14.08 150 51235 179127 110358787
Blister 21.44 14.08 46 51339 227330 110310584
Rash erythematous 21.42 14.08 85 51300 81747 110456167
Vomiting 21.40 14.08 564 50821 910111 109627803
Haemolysis 21.24 14.08 31 51354 15608 110522306
Joint stiffness 21.22 14.08 3 51382 67240 110470674
Anticoagulation drug level below therapeutic 21.22 14.08 12 51373 1722 110536192
Product quality issue 21.07 14.08 5 51380 77294 110460620
Biopsy liver abnormal 21.04 14.08 8 51377 461 110537453
Premature delivery 21.04 14.08 45 51340 30587 110507327
Therapeutic product effect decreased 20.96 14.08 52 51333 244264 110293650
Cell death 20.83 14.08 19 51366 5772 110532142
Type III immune complex mediated reaction 20.66 14.08 10 51375 1043 110536871
Erythema multiforme 20.64 14.08 36 51349 21061 110516853
Paraesthesia 20.63 14.08 63 51322 276458 110261456
Anuria 20.60 14.08 39 51346 24302 110513612
Skin reaction 20.58 14.08 36 51349 21108 110516806
Hilar lymphadenopathy 20.54 14.08 13 51372 2289 110535625
Atypical mycobacterial lower respiratory tract infection 20.49 14.08 7 51378 296 110537618
Blood alkaline phosphatase increased 20.47 14.08 76 51309 70859 110467055
Pulmonary fibrosis 20.36 14.08 11 51374 102031 110435883
Prescribed underdose 20.35 14.08 3 51382 65171 110472743
Lymph node abscess 20.35 14.08 5 51380 63 110537851
Mastitis bacterial 20.35 14.08 5 51380 63 110537851
Cryptococcosis 20.29 14.08 17 51368 4614 110533300
Leukocytosis 20.23 14.08 63 51322 53765 110484149
Psoas abscess 20.03 14.08 11 51374 1491 110536423
Breast discomfort 19.95 14.08 8 51377 532 110537382
Autism spectrum disorder 19.92 14.08 12 51373 1936 110535978
Skin odour abnormal 19.78 14.08 13 51372 2441 110535473
Pulmonary toxicity 19.65 14.08 32 51353 17714 110520200
Nephrotic syndrome 19.64 14.08 28 51357 13803 110524111
COVID-19 19.62 14.08 54 51331 245006 110292908
Limbal swelling 19.54 14.08 4 51381 20 110537894
Cross sensitivity reaction 19.51 14.08 18 51367 5549 110532365
Pulmonary granuloma 19.28 14.08 13 51372 2548 110535366
Hepatosplenic abscess 19.22 14.08 4 51381 22 110537892
Gait inability 19.19 14.08 21 51364 136355 110401559
Synovial cyst 19.04 14.08 25 51360 11405 110526509
Coronary artery disease 18.84 14.08 5 51380 71685 110466229
Dyschromatopsia 18.72 14.08 10 51375 1284 110536630
Wound drainage 18.64 14.08 10 51375 1294 110536620
Orthostatic hypotension 18.63 14.08 4 51381 66245 110471669
Nocardiosis 18.46 14.08 20 51365 7466 110530448
Hepatic haemorrhage 18.43 14.08 10 51375 1324 110536590
Cat scratch disease 18.36 14.08 8 51377 655 110537259
Purpura non-thrombocytopenic 18.33 14.08 6 51379 222 110537692
Psychiatric symptom 18.30 14.08 22 51363 9191 110528723
Coagulation factor X level decreased 18.29 14.08 5 51380 98 110537816
Palmoplantar pustulosis 18.26 14.08 9 51376 977 110536937
Ocular icterus 18.23 14.08 18 51367 6035 110531879
Marrow hyperplasia 18.20 14.08 11 51374 1785 110536129
Lung disorder 18.18 14.08 35 51350 180012 110357902
Prothrombin level decreased 18.12 14.08 11 51374 1799 110536115
Subacute hepatic failure 18.10 14.08 6 51379 231 110537683
Sedation 18.05 14.08 5 51380 69678 110468236
Wrong technique in product usage process 18.04 14.08 9 51376 87339 110450575
Antimicrobial susceptibility test resistant 18.03 14.08 7 51378 427 110537487
Axonal neuropathy 18.01 14.08 12 51373 2306 110535608
Tear discolouration 17.95 14.08 3 51382 3 110537911
Deafness neurosensory 17.54 14.08 22 51363 9597 110528317
Balance disorder 17.48 14.08 17 51368 116543 110421371
Fixed eruption 17.45 14.08 15 51370 4217 110533697
Therapeutic product effect incomplete 17.41 14.08 50 51335 223755 110314159
Testicular mass 17.34 14.08 5 51380 120 110537794
Preterm premature rupture of membranes 17.24 14.08 10 51375 1505 110536409
Hyperglycaemia 17.23 14.08 9 51376 85081 110452833
Clostridium difficile colitis 17.16 14.08 52 51333 43726 110494188
Skin plaque 17.08 14.08 25 51360 12620 110525294
Shunt infection 17.01 14.08 6 51379 279 110537635
Gait disturbance 16.99 14.08 69 51316 278139 110259775
Nephritic syndrome 16.96 14.08 7 51378 501 110537413
Speech disorder 16.74 14.08 4 51381 61565 110476349
Post treatment Lyme disease syndrome 16.73 14.08 3 51382 6 110537908
Pericarditis lupus 16.70 14.08 4 51381 45 110537869
Eosinophilic myocarditis 16.70 14.08 11 51374 2074 110535840
Implant site infection 16.61 14.08 11 51374 2092 110535822
Full blood count abnormal 16.57 14.08 3 51382 56049 110481865
Hepatorenal syndrome 16.37 14.08 15 51370 4582 110533332
Prothrombin time prolonged 16.30 14.08 29 51356 17232 110520682
Extrapulmonary tuberculosis 16.29 14.08 7 51378 554 110537360
Drug level abnormal 16.22 14.08 7 51378 560 110537354
Trichoglossia 16.20 14.08 8 51377 872 110537042
Blepharospasm 16.07 14.08 3 51382 54848 110483066
Lung consolidation 16.06 14.08 22 51363 10454 110527460
Bilirubin conjugated increased 16.01 14.08 17 51368 6207 110531707
Peritoneal tuberculosis 15.96 14.08 7 51378 583 110537331
White blood cell count decreased 15.89 14.08 54 51331 229336 110308578
Tuberculid 15.87 14.08 3 51382 9 110537905
Hepatitis A virus test positive 15.83 14.08 4 51381 57 110537857
Malabsorption from administration site 15.82 14.08 5 51380 165 110537749
Hyperuricaemia 15.81 14.08 26 51359 14505 110523409
Epstein-Barr virus test positive 15.75 14.08 9 51376 1317 110536597
Mucosal inflammation 15.63 14.08 13 51372 96128 110441786
Pseudomembranous colitis 15.63 14.08 17 51368 6374 110531540
Endocarditis bacterial 15.63 14.08 10 51375 1795 110536119
Cardiac disorder 15.54 14.08 8 51377 76272 110461642
Bullous haemorrhagic dermatosis 15.54 14.08 6 51379 361 110537553
Rebound effect 15.45 14.08 26 51359 14780 110523134
Oxygen saturation decreased 15.43 14.08 31 51354 156951 110380963
Leprosy 15.38 14.08 5 51380 181 110537733
Glomerular filtration rate abnormal 15.36 14.08 11 51374 2372 110535542
Diabetes insipidus 15.25 14.08 17 51368 6553 110531361
Human herpesvirus 6 infection 15.22 14.08 17 51368 6564 110531350
CD4/CD8 ratio decreased 15.11 14.08 4 51381 69 110537845
Product use issue 15.11 14.08 84 51301 311611 110226303
Intentional product misuse 15.09 14.08 24 51361 132880 110405034
Skin test positive 15.01 14.08 9 51376 1440 110536474
Drug effective for unapproved indication 14.95 14.08 25 51360 14142 110523772
Subcutaneous abscess 14.94 14.08 20 51365 9297 110528617
Pneumonia lipoid 14.92 14.08 5 51380 199 110537715
Hot flush 14.90 14.08 6 51379 66030 110471884
Pneumothorax 14.86 14.08 43 51342 35242 110502672
Scar excision 14.85 14.08 4 51381 74 110537840
Haemoptysis 14.74 14.08 69 51316 71285 110466629
Gamma-glutamyltransferase increased 14.71 14.08 62 51323 61247 110476667
Coma hepatic 14.68 14.08 8 51377 1069 110536845
Drug metabolising enzyme increased 14.66 14.08 3 51382 15 110537899
Human herpesvirus 7 infection 14.64 14.08 5 51380 211 110537703
Necrosis 14.62 14.08 22 51363 11384 110526530
Blood creatine phosphokinase increased 14.61 14.08 70 51315 73007 110464907
Live birth 14.59 14.08 7 51378 69477 110468437
Liver abscess 14.59 14.08 18 51367 7721 110530193
Angina bullosa haemorrhagica 14.58 14.08 5 51380 214 110537700
Mast cell activation syndrome 14.57 14.08 9 51376 1519 110536395
Hip arthroplasty 14.46 14.08 4 51381 55809 110482105
Femoral artery aneurysm 14.44 14.08 5 51380 220 110537694
Swollen tongue 14.43 14.08 5 51380 60357 110477557
Neoplasm progression 14.36 14.08 6 51379 64589 110473325
Total bile acids increased 14.33 14.08 4 51381 85 110537829
Computerised tomogram abnormal 14.33 14.08 13 51372 3923 110533991
Vitamin K decreased 14.29 14.08 4 51381 86 110537828
Nicotinic acid deficiency 14.21 14.08 5 51380 231 110537683
Chylothorax 14.15 14.08 8 51377 1148 110536766
Chronic allograft nephropathy 14.14 14.08 10 51375 2116 110535798
Hospitalisation 14.13 14.08 28 51357 142465 110395449
Dysbiosis 14.11 14.08 10 51375 2122 110535792

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC J04AB02 ANTIINFECTIVES FOR SYSTEMIC USE
ANTIMYCOBACTERIALS
DRUGS FOR TREATMENT OF TUBERCULOSIS
Antibiotics
ATC J04AM02 ANTIINFECTIVES FOR SYSTEMIC USE
ANTIMYCOBACTERIALS
DRUGS FOR TREATMENT OF TUBERCULOSIS
Combinations of drugs for treatment of tuberculosis
ATC J04AM05 ANTIINFECTIVES FOR SYSTEMIC USE
ANTIMYCOBACTERIALS
DRUGS FOR TREATMENT OF TUBERCULOSIS
Combinations of drugs for treatment of tuberculosis
ATC J04AM06 ANTIINFECTIVES FOR SYSTEMIC USE
ANTIMYCOBACTERIALS
DRUGS FOR TREATMENT OF TUBERCULOSIS
Combinations of drugs for treatment of tuberculosis
ATC J04AM07 ANTIINFECTIVES FOR SYSTEMIC USE
ANTIMYCOBACTERIALS
DRUGS FOR TREATMENT OF TUBERCULOSIS
Combinations of drugs for treatment of tuberculosis
ATC J04AM12 ANTIINFECTIVES FOR SYSTEMIC USE
ANTIMYCOBACTERIALS
DRUGS FOR TREATMENT OF TUBERCULOSIS
Combinations of drugs for treatment of tuberculosis
ATC J04BA50 ANTIINFECTIVES FOR SYSTEMIC USE
ANTIMYCOBACTERIALS
DRUGS FOR TREATMENT OF LEPRA
Drugs for treatment of lepra
ATC J04BA51 ANTIINFECTIVES FOR SYSTEMIC USE
ANTIMYCOBACTERIALS
DRUGS FOR TREATMENT OF LEPRA
Drugs for treatment of lepra
FDA CS M0019113 Rifamycins
FDA EPC N0000175500 Rifamycin Antibacterial
MeSH PA D000890 Anti-Infective Agents
MeSH PA D000900 Anti-Bacterial Agents
MeSH PA D000904 Antibiotics, Antitubercular
MeSH PA D000995 Antitubercular Agents
MeSH PA D004791 Enzyme Inhibitors
MeSH PA D007917 Leprostatic Agents
MeSH PA D019384 Nucleic Acid Synthesis Inhibitors
MeSH PA D065695 Cytochrome P-450 CYP2B6 Inducers
MeSH PA D065696 Cytochrome P-450 CYP2C8 Inducers
MeSH PA D065697 Cytochrome P-450 CYP2C19 Inducers
MeSH PA D065698 Cytochrome P-450 CYP2C9 Inducers
MeSH PA D065701 Cytochrome P-450 CYP3A Inducers
CHEBI has role CHEBI:22587 antiviral agent
CHEBI has role CHEBI:33231 antitubercular agent
CHEBI has role CHEBI:33281 antimicrobial agent
CHEBI has role CHEBI:33282 antibacterial agent
CHEBI has role CHEBI:35441 antiinfective agent
CHEBI has role CHEBI:35480 analgesic
CHEBI has role CHEBI:35526 hypoglycemic agent
CHEBI has role CHEBI:35554 cardiovascular drug
CHEBI has role CHEBI:35610 antineoplastic agent
CHEBI has role CHEBI:35620 vasodilator agent
CHEBI has role CHEBI:35674 antihypertensive agent
CHEBI has role CHEBI:35705 immunosuppressive agent
CHEBI has role CHEBI:35718 antifungal agent
CHEBI has role CHEBI:35816 leprostatic drug
CHEBI has role CHEBI:35842 antirheumatic drug
CHEBI has role CHEBI:37416 EC 2.7.7.6 (RNA polymerase) inhibitor
CHEBI has role CHEBI:48001 protein synthesis inhibitor
CHEBI has role CHEBI:48407 antiparkinson drug
CHEBI has role CHEBI:48422 angiogenesis inhibitor
CHEBI has role CHEBI:49201 anti-ulcer drug
CHEBI has role CHEBI:50249 anticoagulant
CHEBI has role CHEBI:50503 laxative
CHEBI has role CHEBI:50919 antiemetic
CHEBI has role CHEBI:59517 DNA synthesis inhibitor
CHEBI has role CHEBI:63726 neuroprotective agent
CHEBI has role CHEBI:64946 anti-HIV agent
CHEBI has role CHEBI:64951 anti-HBV agent
CHEBI has role CHEBI:76971 <em>Escherichia coli</em> metabolite
CHEBI has role CHEBI:77318 pregnane X receptor agonist
CHEBI has role CHEBI:171664 antiamoebic agent
CHEBI has role CHEBI:176497 geroprotector
CHEBI has role CHEBI:233423 antifibrotic agent

Related Drugs by ATC class:

J04AB Antibiotics 6 drugs
capreomycincycloserineenviomycinrifabutinrifamycinrifapentine
J04AM Combinations of drugs for treatment of tuberculosis 11 drugs
ethambutolisoniazidlevofloxacinlomefloxacinprotionamidepyrazinamiderifabutinstreptomycinsulfamethoxazolethioacetazonetrimethoprim
J04BA Drugs for treatment of lepra 3 drugs
aldesulfoneclofaziminedapsone

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Inactive tuberculosis indication 11999007
Acute tuberculosis indication 25629007
Pulmonary tuberculosis indication 154283005 DOID:2957
Meningococcus carrier indication 170486006
Prevention of Meningococcal Meningitis indication
Inhalational anthrax off-label use 11389007
Staphylococcal infectious disease off-label use 56038003
Leprosy off-label use 81004002 DOID:1024
Cutaneous anthrax off-label use 84980006 DOID:7426
Gastrointestinal anthrax off-label use 111798006 DOID:13386
Atypical mycobacterial infection off-label use 111812000
Anthrax off-label use 409498004 DOID:7427
Multibacillary leprosy off-label use 416257001
Paucibacillary leprosy off-label use 416483009
Single Lesion Paucibacillary Leprosy off-label use
Haemophilus B Influenzae Prevention off-label use
Synergy for Staphylococcal Osteomyelitis off-label use
Nutritional disorder contraindication 2492009 DOID:374
Suicidal thoughts contraindication 6471006
Alcoholism contraindication 7200002
Jaundice contraindication 18165001
Depressive disorder contraindication 35489007
Acute hepatitis contraindication 37871000
Acute nephropathy contraindication 58574008
Hepatic failure contraindication 59927004
Diabetes mellitus contraindication 73211009 DOID:9351
Gout contraindication 90560007 DOID:13189
Anemia due to enzyme deficiency contraindication 111577008
Pancytopenia contraindication 127034005 DOID:12450
Acute hepatic failure contraindication 197270009
Non-infective meningitis contraindication 230155003
Disease of liver contraindication 235856003 DOID:409
Diabetic - poor control contraindication 268519009
Anemia contraindication 271737000 DOID:2355
Pregnancy, function contraindication 289908002
Thrombocytopenic disorder contraindication 302215000 DOID:1588
Peripheral nerve disease contraindication 302226006
Neutropenic disorder contraindication 303011007 DOID:1227
Aplastic anemia contraindication 306058006 DOID:12449
Porphyria contraindication 418470004
Diabetic peripheral neuropathy contraindication 424736006
Slow acetylator due to N-acetyltransferase enzyme variant contraindication 425079005
Prolonged-Severe Nausea and Vomiting contraindication
Chronic Hepatic Disease contraindication




🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 2.94 acidic
pKa2 7.23 acidic
pKa3 11.03 acidic
pKa4 11.77 acidic
pKa5 12.55 acidic
pKa6 7.83 Basic
pKa7 1.35 Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])		Mechanism
action		Bioact sourceMoA source
ATP-binding cassette sub-family G member 2 Transporter IC50 4.25 CHEMBL
Bile salt export pump Transporter IC50 4.95 CHEMBL
Caspase-1 Enzyme IC50 5.08 DRUG MATRIX
Solute carrier organic anion transporter family member 1B1 Transporter INHIBITOR Ki 5.96 IUPHAR
Lanosterol 14-alpha demethylase Enzyme IC50 4.52 CHEMBL
Solute carrier organic anion transporter family member 1A2 Transporter INHIBITOR Ki 4.29 IUPHAR
Solute carrier organic anion transporter family member 1B3 Transporter INHIBITOR IC50 5.80 IUPHAR
Glutathione S-transferase omega-1 Enzyme IC50 4.12 CHEMBL
Nuclear receptor subfamily 1 group I member 2 Nuclear hormone receptor EC50 5.64 CHEMBL
Alpha-synuclein Transporter IC50 5.15 CHEMBL
DNA-directed RNA polymerase subunit beta Enzyme INHIBITOR DRUGBANK CHEMBL
Enoyl-[acyl-carrier-protein] reductase [NADH] Enzyme IC50 7.52 CHEMBL
Arachidonate 15-lipoxygenase Enzyme IC50 5.53 DRUG MATRIX
Bile salt export pump Transporter IC50 4.46 CHEMBL

External reference:

IDSource
4018619 VUID
N0000146932 NUI
D00211 KEGG_DRUG
4018619 VANDF
CHEBI:28077 CHEBI
RFP PDB_CHEM_ID
CHEMBL374478 ChEMBL_ID
2765 IUPHAR_LIGAND_ID
DB01045 DRUGBANK_ID
202953 RXNORM
1197 MMSL
1207 MMSL
5424 MMSL
d00047 MMSL
002789 NDDF
29175007 SNOMEDCT_US
387159009 SNOMEDCT_US
C0035608 UMLSCUI
D012293 MESH_DESCRIPTOR_UI
135398735 PUBCHEM_CID
2323 INN_ID
VJT6J7R4TR UNII
VJT6J7R4TR INXIGHT DRUGS

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Rifadin IV HUMAN PRESCRIPTION DRUG LABEL 1 0068-0597 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 600 mg INTRAVENOUS NDA 27 sections
Rifadin IV HUMAN PRESCRIPTION DRUG LABEL 1 0068-0597 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 600 mg INTRAVENOUS NDA 27 sections
Rifadin IV NOVAPLUS HUMAN PRESCRIPTION DRUG LABEL 1 0068-0599 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 600 mg INTRAVENOUS NDA 27 sections
Rifampin HUMAN PRESCRIPTION DRUG LABEL 1 0143-9230 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 600 mg INTRAVENOUS ANDA 26 sections
rifampin HUMAN PRESCRIPTION DRUG LABEL 1 0904-7315 CAPSULE 300 mg ORAL ANDA 12 sections
Rifampin HUMAN PRESCRIPTION DRUG LABEL 1 17478-151 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 600 mg INTRAVENOUS ANDA 25 sections
Rifampin HUMAN PRESCRIPTION DRUG LABEL 1 21695-527 CAPSULE 300 mg ORAL ANDA 21 sections
RIFAMPIN HUMAN PRESCRIPTION DRUG LABEL 1 24658-801 CAPSULE 150 mg ORAL ANDA 22 sections
RIFAMPIN HUMAN PRESCRIPTION DRUG LABEL 1 24658-802 CAPSULE 300 mg ORAL ANDA 22 sections
Rifampin HUMAN PRESCRIPTION DRUG LABEL 1 42254-039 CAPSULE 300 mg ORAL ANDA 26 sections
RIFAMPIN HUMAN PRESCRIPTION DRUG LABEL 1 42806-799 CAPSULE 300 mg ORAL ANDA 22 sections
RIFAMPIN HUMAN PRESCRIPTION DRUG LABEL 1 42806-801 CAPSULE 150 mg ORAL ANDA 22 sections
Rifampin HUMAN PRESCRIPTION DRUG LABEL 1 50090-0964 CAPSULE 300 mg ORAL ANDA 25 sections
rifampin HUMAN PRESCRIPTION DRUG LABEL 1 50090-5709 CAPSULE 300 mg ORAL ANDA 12 sections
Rifampin HUMAN PRESCRIPTION DRUG LABEL 1 52959-653 CAPSULE, COATED 300 mg ORAL ANDA 25 sections
Rifampin HUMAN PRESCRIPTION DRUG LABEL 1 53002-6430 CAPSULE 300 mg ORAL ANDA 24 sections
rifampin HUMAN PRESCRIPTION DRUG LABEL 1 53002-6431 CAPSULE 300 mg ORAL ANDA 12 sections
Rifampin HUMAN PRESCRIPTION DRUG LABEL 1 53808-0559 CAPSULE, COATED 300 mg ORAL ANDA 22 sections
Rifampin HUMAN PRESCRIPTION DRUG LABEL 1 54868-4683 CAPSULE 300 mg ORAL ANDA 26 sections
Rifampin HUMAN PRESCRIPTION DRUG LABEL 1 54868-5472 CAPSULE 150 mg ORAL ANDA 26 sections
Rifampin HUMAN PRESCRIPTION DRUG LABEL 1 55695-034 CAPSULE 300 mg ORAL ANDA 25 sections
Rifampin HUMAN PRESCRIPTION DRUG LABEL 1 55695-036 CAPSULE 150 mg ORAL ANDA 25 sections
Rifampin HUMAN PRESCRIPTION DRUG LABEL 1 60687-575 CAPSULE 150 mg ORAL ANDA 12 sections
Rifampin HUMAN PRESCRIPTION DRUG LABEL 1 60687-586 CAPSULE 300 mg ORAL ANDA 12 sections
Rifampin HUMAN PRESCRIPTION DRUG LABEL 1 62135-315 CAPSULE 150 mg ORAL ANDA 12 sections
Rifampin HUMAN PRESCRIPTION DRUG LABEL 1 62135-316 CAPSULE 300 mg ORAL ANDA 12 sections
Rifampin HUMAN PRESCRIPTION DRUG LABEL 1 63323-351 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 600 mg INTRAVENOUS ANDA 24 sections
RIFAMPIN HUMAN PRESCRIPTION DRUG LABEL 1 67046-1605 CAPSULE 150 mg ORAL ANDA 21 sections
Rifampin HUMAN PRESCRIPTION DRUG LABEL 1 67457-445 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 600 mg INTRAVENOUS ANDA 22 sections
Rifampin HUMAN PRESCRIPTION DRUG LABEL 1 68151-0985 CAPSULE, COATED 300 mg ORAL ANDA 25 sections